piqray
Preclinical
Novartispiqray is one of 57 therapeutic programs targeting Breast Carcinoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
56
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
65 competitors in Breast Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerApproved
Afinitor
NovartisApproved
Adriamycin
PfizerApproved
Tagrisso
AstraZenecaApproved
Gemzar
Johnson & JohnsonApproved
Tykerb
NovartisApproved
Piqray
NovartisApproved
Mektovi
PfizerApproved
Aliqopa
BayerApproved
Lynparza
AstraZenecaApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for piqray. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company